PH26816A - Diol-containing renin inhibitors - Google Patents

Diol-containing renin inhibitors Download PDF

Info

Publication number
PH26816A
PH26816A PH38698A PH38698A PH26816A PH 26816 A PH26816 A PH 26816A PH 38698 A PH38698 A PH 38698A PH 38698 A PH38698 A PH 38698A PH 26816 A PH26816 A PH 26816A
Authority
PH
Philippines
Prior art keywords
nhch
cad
phe
mmole
lower alkyl
Prior art date
Application number
PH38698A
Other languages
English (en)
Inventor
Richard Himmelsbach
John Cooke Hodges
James Stanley Kaltenbronn
Joseph Thomas Repine
Ila Sircar
William Chester Patt
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Priority to PH40714A priority Critical patent/PH27036A/en
Publication of PH26816A publication Critical patent/PH26816A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PH38698A 1988-05-27 1989-05-25 Diol-containing renin inhibitors PH26816A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PH40714A PH27036A (en) 1988-05-27 1990-06-21 Process for the preparation of diol containing renin inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19999088A 1988-05-27 1988-05-27
US07/321,638 US5036053A (en) 1988-05-27 1989-03-15 Diol-containing renin inhibitors

Publications (1)

Publication Number Publication Date
PH26816A true PH26816A (en) 1992-11-05

Family

ID=26895354

Family Applications (1)

Application Number Title Priority Date Filing Date
PH38698A PH26816A (en) 1988-05-27 1989-05-25 Diol-containing renin inhibitors

Country Status (11)

Country Link
US (1) US5036053A (de)
EP (1) EP0343654A3 (de)
JP (1) JPH0267297A (de)
KR (1) KR900018137A (de)
AU (1) AU625456B2 (de)
DK (1) DK258589A (de)
FI (1) FI892521L (de)
NO (1) NO892136L (de)
NZ (1) NZ229281A (de)
PH (1) PH26816A (de)
PT (1) PT90659B (de)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2058489T3 (es) * 1988-01-26 1994-11-01 Sankyo Co Oligopeptidos con actividades inhibidoras de la renina, su preparacion y su uso.
US5238923A (en) * 1989-05-26 1993-08-24 Warner-Lambert Company Amino-substituted heterocycles as renin inhibitors
IE68045B1 (en) * 1990-05-11 1996-05-15 Abbott Lab Renin inhibitors
WO1993006127A1 (en) * 1991-09-17 1993-04-01 Warner-Lambert Company Novel amino acid prodrug renin inhibitors
US5223535A (en) * 1991-10-29 1993-06-29 G. D. Searle & Co. Propargyl glycine amino propargyl diol compounds for treatment of hypertension
EP0539976A1 (de) * 1991-10-29 1993-05-05 G.D. Searle & Co. Ethynyl-Alanin-Amino-Diolderivate zur Behandlung von Hypertonie
US5227401A (en) * 1991-10-29 1993-07-13 G. D. Searle & Co. Ethynyl alanine amino diol compounds for treatment of hypertension
EP0625980A1 (de) * 1992-02-13 1994-11-30 Warner-Lambert Company Verfahren zur herstellung von chiral ethyl(5-amino-1,2-dihydro-2-methyl-3-phenylpyrido [3,4-b] pyrazin-7-yl) carbamat
US5972990A (en) * 1992-04-10 1999-10-26 Brigham And Women's Hospital, Inc. Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
US5252591A (en) 1992-08-14 1993-10-12 G. D. Searle & Company Pyridinyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension
US5373017A (en) * 1992-08-14 1994-12-13 G. D. Searle & Co. Imidazolyl/benzimidazolyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension
US5298505A (en) * 1992-08-14 1994-03-29 G. D. Searle & Co. Ethynyl alanine amino diol compounds having a piperazinyl-terminated group or a piperazinyl-alkylamino-terminated group for treatment of hypertension
ZA98376B (en) * 1997-01-23 1998-07-23 Hoffmann La Roche Sulfamide-metalloprotease inhibitors
US6376506B1 (en) 1997-01-23 2002-04-23 Syntex (U.S.A.) Llc Sulfamide-metalloprotease inhibitors
US6493178B1 (en) * 1997-04-30 2002-12-10 Spectra Logic Corporation Data cartridge library system
US6423688B1 (en) * 1997-07-31 2002-07-23 Athena Neurosciences, Inc. Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4
US6130220A (en) * 1997-10-16 2000-10-10 Syntex (Usa) Inc. Sulfamide-metalloprotease inhibitors
US6407124B1 (en) 1998-06-18 2002-06-18 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
US6410746B1 (en) 1999-04-27 2002-06-25 Research Foundation Of State University Of New York, The Metal cataltsts and methods for making and using same
WO2002048715A2 (en) 2000-12-14 2002-06-20 The Brigham And Women's Hospital, Inc. Inflammatory markers for detection and prevention of diabetes mellitus
AU2002332696A1 (en) 2001-08-27 2003-03-10 The Research Foundation Of State University Of New York Solid support dirhodium catalyst compositions and methods for making and using same
US7030051B2 (en) 2001-08-27 2006-04-18 The Research Foundation Of State University Of New York Dirhodium catalyst compositions and methods for using same
WO2003094856A2 (en) 2002-05-09 2003-11-20 The Brigham And Women's Hospital, Inc. 1l1rl-1 as a cardiovascular disease marker and therapeutic target
US7273616B2 (en) * 2002-05-10 2007-09-25 The Trustees Of Columbia University In The City Of New York Genetically engineered cell lines and systems for propagating Varicella zoster virus and methods of use thereof
EP1670459A4 (de) * 2003-08-20 2009-03-25 Nitromed Inc Nitrosierte und nitrosylierte kardiovaskuläre verbindungen, zusammensetzungen und anwendungsverfahren
CA2536975A1 (en) * 2003-08-28 2005-03-17 Nitromed, Inc. Nitrosated and nitrosylated diuretic compounds, compositions and methods of use
SI2384753T1 (sl) 2003-08-29 2016-06-30 The Brigham And Women's Hospital, Inc. Hidantoinski derivati kot inhibitorji celične nekroze
US7781219B2 (en) 2003-12-05 2010-08-24 The Cleveland Clinic Foundation Risk markers for cardiovascular disease
CA2554716A1 (en) * 2004-01-22 2005-08-04 Nitromed, Inc. Nitrosated and/or nitrosylated compounds, compositions and methods of use
US7803838B2 (en) * 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
WO2006041855A2 (en) 2004-10-04 2006-04-20 Nitromed, Inc. Compositions and methods using apocynin compounds and nitric oxide donors
DK1809759T3 (da) 2004-10-06 2014-01-06 Brigham & Womens Hospital Relevans af opnåede niveauer af markører for systemisk inflammation efter behandling
US20080275093A1 (en) * 2004-11-15 2008-11-06 Nitromed, Inc. Diuretic Compounds Comprising Heterocyclic Nitric Oxide Donor Groups, Compositions and Methods of Use
AU2006206249A1 (en) * 2005-01-21 2006-07-27 Nicox S.A. Cardiovascular compounds comprising heterocyclic nitric oxide donor group compositions and methods of use
AU2006210952B2 (en) * 2005-01-31 2011-08-04 Mylan Laboratories, Inc. Pharmaceutical composition comprising hydroxylated nebivolol
CA2597422A1 (en) * 2005-02-16 2007-08-02 Nitromed, Inc. Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use
JP2008531697A (ja) * 2005-02-28 2008-08-14 ニトロメッド インコーポレーティッド 酸化窒素増強基を含む心血管化合物、組成物および使用法
AU2006223392A1 (en) * 2005-03-09 2006-09-21 Nicox S.A. Organic nitric oxide enhancing salts of angiotensin II antagonists, compositions and methods of use
KR101310037B1 (ko) 2005-05-31 2013-09-24 밀란 인크. 네비볼롤을 함유하는 조성물
US7700798B1 (en) 2005-06-08 2010-04-20 The Research Foundation Of State University Of New York Erogorgiaene congeners and methods and intermediates useful in the preparation of same
US7816536B2 (en) * 2005-06-10 2010-10-19 The Research Foundation Of State University Of New York 4-substituted and 7-substituted indoles, benzofurans, benzothiophenes, benzimidazoles, benzoxazoles, and benzothiazoles and methods for making same
US20090018091A1 (en) * 2005-08-02 2009-01-15 Nitromed, Inc. Nitric Oxide Enhancing Antimicrobial Compounds, Compositions and Methods of Use
WO2007041681A2 (en) * 2005-10-04 2007-04-12 Nitromed, Inc. Methods for treating respiratory disorders
US8119358B2 (en) * 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
WO2007059311A2 (en) * 2005-11-16 2007-05-24 Nitromed, Inc. Furoxan compounds, compositions and methods of use
US7385064B1 (en) 2005-11-30 2008-06-10 The Research Foundation Of State University Of New York Catalysts for use in enantioselective synthesis
US20080293702A1 (en) * 2005-12-22 2008-11-27 Nitromed, Inc. Nitric Oxide Enhancing Pyruvate Compounds, Compositions and Methods of Use
US20080057590A1 (en) 2006-06-07 2008-03-06 Mickey Urdea Markers associated with arteriovascular events and methods of use thereof
EP2081892A4 (de) 2006-11-17 2014-03-05 Donald F Weaver Verbindungen und verfahren zur behandlung von proteinfaltungserkrankungen
CA2684308A1 (en) 2007-04-18 2008-10-30 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
US7828840B2 (en) * 2007-11-15 2010-11-09 Med Institute, Inc. Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists
US8741910B2 (en) 2008-11-25 2014-06-03 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
JP2012511002A (ja) 2008-12-05 2012-05-17 メルク・シャープ・エンド・ドーム・コーポレイション アンジオテンシンｉｉ受容体アンタゴニストとしてのニトロオキシ誘導体
JP5075145B2 (ja) 2009-02-13 2012-11-14 トヨタ自動車株式会社 内燃機関の制御装置
MX2011008952A (es) 2009-02-26 2011-09-27 Merck Sharp & Dohme Activadores de guanilato ciclasa solubles.
WO2011094730A2 (en) 2010-02-01 2011-08-04 The Hospital For Sick Children Remote ischemic conditioning for treatment and reventon of restenosis
CN102939054A (zh) 2010-03-31 2013-02-20 儿童医院 远端缺血处理改进心肌梗死之后的结果的用途
EP2571351B1 (de) 2010-05-21 2016-09-14 Merck Sharp & Dohme Corp. Diazeniumdiolat-cyclohexyl-derivate
MX2013004739A (es) 2010-10-29 2013-07-02 Merck Sharp & Dohme Derivados heterociclicos de diazenodiolato.
CN103384661B (zh) 2011-01-20 2016-08-10 默沙东公司 盐皮质激素受体拮抗剂
JO3350B1 (ar) 2011-03-07 2019-03-13 Merck Sharp & Dohme مشتقات حلقية غير متجانسة محتوية على مجموعات أمينو أولية ومركبات داي أزينيومديولات
US9487506B2 (en) 2011-04-13 2016-11-08 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
WO2012148808A1 (en) 2011-04-26 2012-11-01 Merck Sharp & Dohme Corp. Aldosterone synthase inhibitors
US9272987B2 (en) 2011-05-02 2016-03-01 Merck Sharp & Dohme Corp. Diazeniumdiolate cyclohexyl derivatives
JO3210B1 (ar) 2011-10-28 2018-03-08 Merck Sharp & Dohme مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة
US9139585B2 (en) 2011-10-31 2015-09-22 Merck Sharp & Dohme Corp. Inhibitors of the Renal Outer Medullary Potassium channel
US9108947B2 (en) 2011-10-31 2015-08-18 Merck Sharp & Dohme Corp. Inhibitors of the Renal Outer Medullary Potassium channel
SG11201407402TA (en) 2012-05-11 2014-12-30 Reset Therapeutics Inc Carbazole-containing sulfonamides as cryptochrome modulators
AR092031A1 (es) 2012-07-26 2015-03-18 Merck Sharp & Dohme Inhibidores del canal de potasio medular externo renal
EP2879666B1 (de) 2012-08-01 2020-04-08 Tavakoli, Zahra Freifliessende gefrorene zusammensetzungen mit einem therapeutischen mittel
WO2014085210A1 (en) 2012-11-29 2014-06-05 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9717714B2 (en) 2012-12-19 2017-08-01 Merck Sharp & Dohme Corp. Spirocyclic CETP inhibitors
US9725452B2 (en) 2013-03-15 2017-08-08 Presidents And Fellows Of Harvard College Substituted indoles and pyrroles as RIP kinase inhibitors
US9783552B2 (en) 2013-12-11 2017-10-10 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
US9611278B2 (en) 2013-12-11 2017-04-04 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
US10000484B2 (en) 2013-12-18 2018-06-19 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassim channel
TWI690521B (zh) 2014-04-07 2020-04-11 美商同步製藥公司 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
WO2015183938A1 (en) 2014-05-29 2015-12-03 Geneticure Llc Improved therapeutic regimen for hypertension
EP3174537B1 (de) 2014-07-29 2021-06-23 Merck Sharp & Dohme Corp. Monocyclische isoxazoline als hemmer des cholesterinestertransferproteins
MY186702A (en) 2014-10-31 2021-08-11 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
TW201625635A (zh) 2014-11-21 2016-07-16 默沙東藥廠 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物
WO2016191334A1 (en) 2015-05-27 2016-12-01 Merck Sharp & Dohme Corp. Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
EP3310782B1 (de) 2015-05-28 2021-12-01 Merck Sharp & Dohme Corp. Als lösliche guanylat-cyclase-aktivatoren geeignete imidazopyrazinylderivate
EP3322420B1 (de) 2015-07-13 2021-12-29 Merck Sharp & Dohme Corp. Bicyclische heterocyclen als inhibitoren des cholesterinestertransferproteins
WO2017107052A1 (en) 2015-12-22 2017-06-29 Merck Sharp & Dohme Corp. Soluble guanylate cyclase stimulators
WO2017197555A1 (en) 2016-05-16 2017-11-23 Merck Sharp & Dohme Corp. Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators
US12440496B2 (en) 2019-05-22 2025-10-14 Merck Sharp & Dohme Llc Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes
WO2020236690A1 (en) 2019-05-22 2020-11-26 Merck Sharp & Dohme Corp. Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes
ES3048448T3 (en) 2020-07-22 2025-12-10 Janssen Pharmaceutica Nv Compounds useful as factor xia inhibitors
US11814364B2 (en) 2021-03-18 2023-11-14 Janssen Pharmaceutica Nv Pyridine N-oxide derivatives useful as factor XIa inhibitors
US11919881B2 (en) 2021-03-18 2024-03-05 Janssen Pharmaceutica Nv Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11845748B2 (en) 2021-03-18 2023-12-19 Janssen Pharmaceutica Nv Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11897880B2 (en) 2021-04-30 2024-02-13 Janssen Pharmaceutica Nv 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors
US12286429B2 (en) 2021-07-22 2025-04-29 Janssen Pharmaceutica Nv 5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide derivatives useful as a factor XIa inhibitors
US11958856B2 (en) 2021-07-22 2024-04-16 Janssen Pharmaceutica Nv Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4845079A (en) * 1985-01-23 1989-07-04 Luly Jay R Peptidylaminodiols
EP0249096B1 (de) * 1986-06-10 1995-01-11 Merck Patent Gmbh Reninhemmende Aminosäurederivate.

Also Published As

Publication number Publication date
EP0343654A3 (de) 1991-05-29
EP0343654A2 (de) 1989-11-29
DK258589A (da) 1989-11-28
PT90659A (pt) 1989-11-30
NZ229281A (en) 1991-11-26
FI892521A7 (fi) 1989-11-28
JPH0267297A (ja) 1990-03-07
AU625456B2 (en) 1992-07-09
NO892136L (no) 1989-11-28
NO892136D0 (no) 1989-05-26
DK258589D0 (da) 1989-05-26
AU3463389A (en) 1989-11-30
FI892521A0 (fi) 1989-05-24
US5036053A (en) 1991-07-30
KR900018137A (ko) 1990-12-20
FI892521L (fi) 1989-11-28
PT90659B (pt) 1994-10-31

Similar Documents

Publication Publication Date Title
PH26816A (en) Diol-containing renin inhibitors
US5036054A (en) Renin inhibitors containing alpha-heteroatom amino acids
US5071837A (en) Novel renin inhibiting peptides
US5034512A (en) Branched backbone renin inhibitors
US5063207A (en) Renin inhibitors, method for using them, and compositions containing them
EP0517589B1 (de) Tachykininderivate, deren Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
CA1261546A (en) N - (acyldipeptidyl) - aminoglycols
JPH02300199A (ja) レトロウイルスプロテアーゼ阻害剤
US4804743A (en) Proline-containing renin inhibitors
US5238923A (en) Amino-substituted heterocycles as renin inhibitors
AU605212B2 (en) Renin-inhibitors III
US5221667A (en) Renin inhibiting peptides having an α-heteroatom amino acid at the P3 position
US5198426A (en) Renin inhibitors containing c-terminal dihydroxy amides
US5219851A (en) Tetrahydroisoquinoline-type renin inhibiting peptides
US5260278A (en) Diol-containing renin inhibitors
WO1989003841A1 (en) Renin inhibitors, processes for preparing them, methods for using them, and compositions containing them
US4735933A (en) Renin inhibitors III
US5149692A (en) Bisalkoxyphosphinyl compounds as renin inhibitors
EP0222523A2 (de) Difluorcyclostatin enthaltende Polypeptide
US5126451A (en) Renin inhibitors containing α-heteroatom amino acids
EP0275480A2 (de) Renin-Inhibitoren-IV
US5162527A (en) Renin inhibitors, processes for preparing them, methods for using them, and compositions containing them
PH27036A (en) Process for the preparation of diol containing renin inhibitors
EP0297816A2 (de) Homocyclostatin und Cyclostatin enthaltende Polypeptide als Antihypertensiva